The Oncology Institute, Inc. TOI Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -6%+1.2pp | -7.2%+1.7pp | -8.9%+2.1pp | -11.1%+1.9pp | -12.9%+2.4pp | |
| Net margin | -8%+4.1pp | -12.1%+2.3pp | -14.4%+1.1pp | -15.5%+0.4pp | -16%+0.5pp | |
| EBITDA margin | -4.7%+1.0pp | -5.8%+1.6pp | -7.4%+2.0pp | -9.4%+1.8pp | -11.3%+2.4pp | |
| Returns | ||||||
| Return on assets | -26.2%+9.7pp | -35.9%+2.7pp | -38.7%+0.2pp | -38.8%-3.9pp | -34.9%-1.1pp | |
| Return on invested capital | -51.8%+3.0pp | -54.8%-1.8pp | -53.1%-0.4pp | -52.7%+1.2pp | -53.9%+0.6pp | |
| Efficiency | ||||||
| Asset turnover | 3.3×+0.3× | 3×+0.3× | 2.7×+0.2× | 2.5×+0.3× | 2.2×+0.1× | |
| Liquidity | ||||||
| Current ratio | 1.5×-0.1× | 1.6×-0.1× | 1.7×+0.1× | 1.6×-0.2× | 1.8×-0.4× | |
| Quick ratio | 1.2×-0.2× | 1.4×0.0× | 1.4×0.0× | 1.4×-0.2× | 1.6×-0.4× | |
| Cash ratio | 0.4×-0.1× | 0.5×+0.1× | 0.4×0.0× | 0.5×-0.2× | 0.7×-0.3× | |
| Leverage | ||||||
| Debt-to-assets | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×-0.1× | |
| Interest coverage | -4.3×-1.1× | -3.2×+0.7× | -3.9×+0.4× | -4.3×+0.4× | -4.7×+3.3× | |
| Per Share | ||||||
| Book value per share | -$0.16+5.9% | -$0.17-35.1% | -$0.13-30.6% | -$0.10-247% | $0.07+37.4% | |
| Valuation | ||||||
| Market capitalization | $511.91M+133% | $350.24M+7.3% | $326.33M+51.1% | $216M+116% | $100.05M+329% | |
| Enterprise value | $586.58M+108% | $420.42M+4.5% | $402.33M+39.2% | $288.98M+77.6% | $162.74M+67.9% | |
| Price / sales | 0.9×+0.4× | 0.7×0.0× | 0.7×+0.2× | 0.5×+0.3× | 0.2×+0.2× | |
| EV / sales | 1.1×+0.4× | 0.8×0.0× | 0.9×+0.2× | 0.7×+0.3× | 0.4×+0.2× | |
| Earnings yield | -8.5%+20.8pp | -17.3%+3.0pp | -20.3%+10.2pp | -30.5%+33.8pp | -64.3%+213pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do The Oncology Institute, Inc.'s ratios come from?
- Every ratio is computed from The Oncology Institute, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
